BioSpace News Archive

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that Ron Mayron has joined its Board of Directors.

Jazz Pharmaceuticals plc announced that its wholly owned subsidiary, Jazz Securities Designated Activity Company, is commencing a private offering of senior secured notes in a transaction exempt from the registration requirements of the Securities Act of 1933, as amended, subject to market and other conditions.

Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, today announced that Stuart Chaffee, PhD, has joined the company as Chief Business Officer.

Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of its IND for TST005 from US FDA for initiating Phase I clinical trial of its bi-functional anti-PD-L1/TGF-β antibody.

AngioSoma, Inc. has hired David Croom as an Executive Vice President. Mr. Croom brings decades of experience in finance, sales, and operations to the AngioSoma team.

BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a pre-clinical-stage biotechnology company focused on harnessing elements of perinatal tissue for use in regenerative therapies; today announced that it has appointed three key members to its scientific advisory board (SAB)

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today the completion of enrollment in its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) infusions to treat COVID-19 induced acute respiratory failure (ARD) or acute respiratory distress syndrome (ARDS).

New Partnership Leverages Medable’s Patient-Centered Cloud Platform, Accelerating Seamless Real-World Data Capture and Fit-for-Purpose Decentralized Solutions

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced a regulatory update for omburtamab, which is an investigational, monoclonal antibody that targets B7-H3

Shields Capital and KNR Therapy, a leader in Applied Behavior Analysis (ABA) that provides individualized treatment to children with Autism Spectrum Disorder (ASD), is proud to announce its recent merger with Forbes Behavioral Services